On 28th April, the most significant overhaul of the UK’s clinical trial regulations in two decades will take full effect. These operational reforms aim to streamline the approval process and provide more agile routes to support innovation, but they also place immediate pressure on trials already in progress, particularly across supply, labelling and regulatory compliance.
In this Q&A, Olive McCormick, Director of Quality at Almac Clinical Services breaks down this change, delving into what sponsors need to address now as the enforcement date approaches and where gaps in readiness could create avoidable risk.
With the new UK clinical trial regulation introducing one of the biggest operational shifts in recent years, where do you see the greatest opportunities for sponsors to gain speed or efficiency in their UK trial programmes?
The new rules represent the most significant overhaul of the UK clinical trial regulations in over 20 years, and will drive impactful change across the board. Notably, this includes the introduction of a streamlined, risk-proportionate approach to trial review.
Under this framework, certain low risk studies can be classified as “notifiable trials,” provided they meet defined criteria. These trials will benefit from an accelerated pathway, and the MHRA expect that around one in five studies will qualify for this fast-track notification route, allowing lower-risk trials to start sooner, enabling experts to focus on complex and early-phase studies.
This creates a meaningful opportunity for sponsors. Faster approvals enable quicker study start-up, earlier patient access to investigational treatments, and improved overall programme timelines. This streamlined approach delivers clear efficiencies for sponsors while also benefiting patients.
The MHRA’s ambition is clear: accelerate study start-up and bring more trials to the UK. From what you’re seeing across the industry, where are sponsors most in need of support to translate that ambition into operational readiness?
While the new regulations cover the full lifecycle of clinical trials, from initiation through to close-out, sponsors are currently less focused on new trials and more concerned with transitional arrangements.
Sponsors are primarily concerned about how their ongoing studies will be affected and how to ensure continuity of supply. Some organisations are well prepared, have a strong understanding of the regulations, and have taken proactive steps to ensure a smooth transition. Others are less familiar and are at greater risk of non-compliance due to gaps in knowledge.
What misconceptions or gaps in interpretation are slowing organisations down, and how can partners help close those gaps?
One of the most significant misconceptions has been around the definition of “product already manufactured.” Early guidance suggested that such product could continue to be used after the April 28th deadline. However, this created uncertainty, as “manufactured” could be interpreted in different ways, such as the point at which the API was added or when the final labelling was applied. This ambiguity led to varying interpretations across the industry. Subsequent clarification confirmed that only product that had been QP certified prior to the deadline could continue to be used. Any product that is not certified and does not meet the new requirements cannot be used.
